The iLite Fc-Effector system comes with a suite of engineered homologues (+) and (-) target cells that allow differences in ADCC and ADCP activity to be determined with precision and specificity. It also enables comparisons of ADCC/ADCP activity between variants of therapeutic antibodies that target the same antigen and possibilities to detect any unwanted activity due to the engineering of the antibody.
Target (+) cells have been engineered to overexpress a specific antigen, either by overactivation of the endogenous expression or by insertion of the gene encoding this antigen. This gives a stable and controlled expression of the antigen on the cell surface and enables target-Fc receptor crosslinking inducing a specific luciferas signal.
Target (-) cells do not present the specific surface target molecule. Hence, no crosslinking between target and Fc-Receptor can be established and no luminescence from the Effector Cell is generated. This specific antigen-negative target cells provides a unique way of detecting nonspecific effects.